Highlights Poxel

Equities

POXEL

FR0012432516

Real-time Euronext Paris Other stock markets 09:17:07 2024-07-10 am EDT			5-day change	1st Jan Change
0.456 ^EUR	-2.67%		-6.94%	-17.24%

Apr. 11	Poxel: CDC falls below the 10% threshold	CF
Feb. 15	Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poxel: share price rises, boosted by savings plan	Dec. 22	CF
Poxel S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Poxel: published cash position for Q1 2023	23-05-19	CF
Global markets live: Burberry, Cisco, Walmart, Alibaba, Charles Schwab...	23-05-18
Poxel: publication of annual results postponed	23-03-22	CF
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology	23-03-07	CI
Poxel Announces Publication in Kidney International of Pxl770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease	23-03-01	CI
Poxel S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-11	CI
Poxel S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-21	CI
Poxel S.A. Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone	22-08-30	CI
Poxel S.A. Announces Pxl065 and Pxl770 Granted Orphan Drug Designation from the U.S. Fda for X Linked Adrenoleukodystrophy	22-05-17	CI
Poxel Announces PXL770 Wins FDA Fast Track Designation for X-Linked Adrenoleukodystrophy	22-04-11	CI
Poxel S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-22	CI
Poxel Announces PXL065 Granted FDA Fast Track Designation for X-Linked Adrenoleukodystrophy	22-02-16	CI
Poxel Presents Data and Plans Pertaining to ALD	21-09-27	CI
POXEL SA Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients	21-09-21	CI
Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes	21-09-10	CI
Global markets live: Amazon, Delivery Hero, Walmart, Broadcom, JD.com, Didi Global...	21-09-03
Global markets live: AT&T, American Airlines, Biogen, Netflix, ABB...	21-07-22
Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases	21-07-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Poxel

Equities

POXEL

FR0012432516

Highlights

Filters